Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Rectal Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Early research (Phase 1)Study completedNCT03841110
What this trial is testing

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsLymphomaGastric Cancer+15 more
Fate Therapeutics 37
Early research (Phase 1)Looking for participantsNCT07318805
What this trial is testing

Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more
Pfizer 260
Testing effectiveness (Phase 2)Looking for participantsNCT07405476
What this trial is testing

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Who this might be right for
Colon CarcinomaColorectal CarcinomaRectal Carcinoma+9 more
Emory University 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT04430738
What this trial is testing

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Who this might be right for
Colorectal CarcinomaGastric AdenocarcinomaGEJ Adenocarcinoma+3 more
Seagen, a wholly owned subsidiary of Pfizer 40